A novel Alzheimer’s disease drug candidate targeting inflammation and fatty acid metabolism

BACKGROUND: CAD-31 is an Alzheimer’s disease (AD) drug candidate that was selected on the basis of its ability to stimulate the replication of human embryonic stem cell-derived neural precursor cells as well as in APPswe/PS1ΔE9 AD mice. To move CAD-31 toward the clinic, experiments were undertaken t...

Descripción completa

Detalles Bibliográficos
Autores principales: Daugherty, Daniel, Goldberg, Joshua, Fischer, Wolfgang, Dargusch, Richard, Maher, Pamela, Schubert, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5513091/
https://www.ncbi.nlm.nih.gov/pubmed/28709449
http://dx.doi.org/10.1186/s13195-017-0277-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5513091/
https://www.ncbi.nlm.nih.gov/pubmed/28709449
http://dx.doi.org/10.1186/s13195-017-0277-3

Ejemplares similares